March 1 (Reuters) - AEterna Zentaris Inc:
* Receives positive opinion for orphan medicinal product designation for
perifosine for the treatment of multiple myeloma from the committee for
orphan medicinal products of the European medicines agency
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Receives positive opinion for orphan medicinal product designation for
perifosine for the treatment of multiple myeloma from the committee for
orphan medicinal products of the European medicines agency
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2010 AFX News
